Our main business
Our cryomicroneedle (CMN) is an innovative drug-device combination product which allows effective storage, transportation, and in situ delivery of living cells, biologics and drugs.
Company profile
Greater Bay Biotechnology (GBBT) is a business supported by City University of Hong Kong (CityU) HK Tech 300 program, HKSTP Ideation program and HKSAR Government Innovation and Technology Fund.
GBBT focuses on the research, development and commercialisation of transdermal drug and cell delivery technology for the treatment of both local and systemic diseases.
banner
banner
banner
=
Multi-award winning
The CMN research was published at Nature Biomedical Engineering in May 2021
Lastest News
GBBT interviewed on TVB
An interview based on the cryomicroneedle (CMN) technology led by Dr. Xu Chenjie at the City University of Hong Kong. It is the world's first microneedle......
Invited to attend the "2023 International Bay Area Summit"
to share
“Connection Hong Kong innovative Biomedical Technology with Greater Bay Area's Industry and Contribute to Society”
For more information
Follow our public account on WeChat for more information.
Let us help you better understand your needs.
Stay close to us
Leave us your contact
Be the first to know about the latest offers and scientific analysis
